Literature DB >> 19047651

Multinormal in vitro distribution model suitable for the distribution of Plasmodium falciparum chemosusceptibility to doxycycline.

Sébastien Briolant1, Meili Baragatti, Philippe Parola, Fabrice Simon, Adama Tall, Cheikh Sokhna, Philippe Hovette, Modeste Mabika Mamfoumbi, Jean-Louis Koeck, Jean Delmont, André Spiegel, Jacky Castello, Jean Pierre Gardair, Jean Francois Trape, Maryvonne Kombila, Philippe Minodier, Thierry Fusai, Christophe Rogier, Bruno Pradines.   

Abstract

The distribution and range of 50% inhibitory concentrations (IC(50)s) of doxycycline were determined for 747 isolates obtained between 1997 and 2006 from patients living in Senegal, Republic of the Congo, and Gabon and patients hospitalized in France for imported malaria. The statistical analysis was designed to answer the specific question of whether Plasmodium falciparum has different phenotypes of susceptibility to doxycycline. A triple normal distribution was fitted to the data using a Bayesian mixture modeling approach. The IC(50) geometric mean ranged from 6.2 microM to 11.1 microM according to the geographical origin, with a mean of 9.3 microM for all 747 parasites. The values for all 747 isolates were classified into three components: component A, with an IC(50) mean of 4.9 microM (+/-2.1 microM [standard deviation]); component B, with an IC(50) mean of 7.7 microM (+/-1.2 microM); and component C, with an IC(50) mean of 17.9 microM (+/-1.4 microM). According to the origin of the P. falciparum isolates, the triple normal distribution was found in each subgroup. However, the proportion of isolates predicted to belong to component B was most important in isolates from Gabon and Congo and in isolates imported from Africa (from 46 to 56%). In Senegal, 55% of the P. falciparum isolates were predicted to be classified as component C. The cutoff of reduced susceptibility to doxycycline in vitro was estimated to be 35 microM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19047651      PMCID: PMC2630600          DOI: 10.1128/AAC.00546-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  Functional, biophysical, and structural bases for antibacterial activity of tigecycline.

Authors:  Matthew W Olson; Alexey Ruzin; Eric Feyfant; Thomas S Rush; John O'Connell; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 2.  A network to monitor antimalarial drug resistance: a plan for moving forward.

Authors:  Carol Hopkins Sibley; Karen I Barnes; William M Watkins; Christopher V Plowe
Journal:  Trends Parasitol       Date:  2007-11-26

3.  Interaction of tetracycline with RNA: photoincorporation into ribosomal RNA of Escherichia coli.

Authors:  R Oehler; N Polacek; G Steiner; A Barta
Journal:  Nucleic Acids Res       Date:  1997-03-15       Impact factor: 16.971

4.  [Study of premunition development in holo- and meso-endemic malaria areas in Dielmo and Ndiop (Senegal): preliminary results, 1990-1994[].

Authors:  C Rogier; J F Trape
Journal:  Med Trop (Mars)       Date:  1995

5.  Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial.

Authors:  C Ohrt; T L Richie; H Widjaja; G D Shanks; J Fitriadi; D J Fryauff; J Handschin; D Tang; B Sandjaja; E Tjitra; L Hadiarso; G Watt; F S Wignall
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

6.  Doxycycline for malaria prophylaxis in Australian soldiers deployed to United Nations missions in Somalia and Cambodia.

Authors:  G D Shanks; P Roessler; M D Edstein; K H Rieckmann
Journal:  Mil Med       Date:  1995-09       Impact factor: 1.437

7.  Indirect inhibition by antibiotics of nucleotide and deoxynucleotide biosynthesis in Plasmodium falciparum.

Authors:  A E Yeo; K H Rieckmann; R I Christopherson
Journal:  Southeast Asian J Trop Med Public Health       Date:  1998-03       Impact factor: 0.267

8.  Oxygen- and time-dependent effects of antibiotics and selected mitochondrial inhibitors on Plasmodium falciparum in culture.

Authors:  A A Divo; T G Geary; J B Jensen
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

9.  The rationale and plan for creating a World Antimalarial Resistance Network (WARN).

Authors:  Carol Hopkins Sibley; Karen I Barnes; Christopher V Plowe
Journal:  Malar J       Date:  2007-09-06       Impact factor: 2.979

10.  World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility.

Authors:  David J Bacon; Ronan Jambou; Thierry Fandeur; Jacques Le Bras; Chansuda Wongsrichanalai; Mark M Fukuda; Pascal Ringwald; Carol Hopkins Sibley; Dennis E Kyle
Journal:  Malar J       Date:  2007-09-06       Impact factor: 2.979

View more
  19 in total

1.  Delayed Onset of Plasmodium falciparum Malaria after Doxycycline Prophylaxis in a Soldier Returning from the Central African Republic.

Authors:  Emilie Javelle; Marylin Madamet; Tiphaine Gaillard; Guillaume Velut; Corinne Surcouf; Rémy Michel; Eric Garnotel; Fabrice Simon; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

2.  Molecular Markers and In Vitro Susceptibility to Doxycycline in Plasmodium falciparum Isolates from Thailand.

Authors:  Tiphaine Gaillard; Kanlaya Sriprawat; Sébastien Briolant; Chirapat Wangsing; Nathalie Wurtz; Meïli Baragatti; Morgane Lavina; Aurélie Pascual; François Nosten; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

3.  Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.

Authors:  Sébastien Briolant; Maud Henry; Claude Oeuvray; Rémy Amalvict; Eric Baret; Eric Didillon; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

4.  Reliability of antimalarial sensitivity tests depends on drug mechanisms of action.

Authors:  Sharon Wein; Marjorie Maynadier; Christophe Tran Van Ba; Rachel Cerdan; Suzanne Peyrottes; Laurent Fraisse; Henri Vial
Journal:  J Clin Microbiol       Date:  2010-03-10       Impact factor: 5.948

5.  Plasmodium falciparum proteome changes in response to doxycycline treatment.

Authors:  Sébastien Briolant; Lionel Almeras; Maya Belghazi; Elodie Boucomont-Chapeaublanc; Nathalie Wurtz; Albin Fontaine; Samuel Granjeaud; Thierry Fusaï; Christophe Rogier; Bruno Pradines
Journal:  Malar J       Date:  2010-05-25       Impact factor: 2.979

6.  In vitro activity of mirincamycin (U24729A) against Plasmodium falciparum isolates from Gabon.

Authors:  Jana Held; Richard Westerman; Peter G Kremsner; Benjamin Mordmüller
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191

Review 7.  The interplay between drug resistance and fitness in malaria parasites.

Authors:  Philip J Rosenthal
Journal:  Mol Microbiol       Date:  2013-08-16       Impact factor: 3.501

8.  Reduced in vitro doxycycline susceptibility in plasmodium falciparum field isolates from Kenya is associated with PfTetQ KYNNNN sequence polymorphism.

Authors:  Angela O Achieng; Luiser A Ingasia; Dennis W Juma; Agnes C Cheruiyot; Charles A Okudo; Redemptah A Yeda; Jelagat Cheruiyot; Hoseah M Akala; Jacob Johnson; Ben Andangalu; Fredrick Eyase; Walter G Z O Jura; Edwin Kamau
Journal:  Antimicrob Agents Chemother       Date:  2014-07-28       Impact factor: 5.191

9.  Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis.

Authors:  Kathrine R Tan; Alan J Magill; Monica E Parise; Paul M Arguin
Journal:  Am J Trop Med Hyg       Date:  2011-04       Impact factor: 2.345

10.  Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study.

Authors:  Bécaye Fall; Aurélie Pascual; Fatoumata D Sarr; Nathalie Wurtz; Vincent Richard; Eric Baret; Yaya Diémé; Sébastien Briolant; Raymond Bercion; Boubacar Wade; Adama Tall; Bruno Pradines
Journal:  Malar J       Date:  2013-03-20       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.